Deep remission from induction chemotherapy predicts favorable long-term survivals in early stage extranodal nasal NK/T-cell lymphoma receiving sequential chemotherapy and radiation

被引:4
|
作者
Qi, Fei [1 ]
Zhou, Wenyuan [2 ]
Xie, Yan [1 ]
Sun, Yan [3 ]
Wu, Meng [1 ]
Chai, Yue [4 ]
Chen, Bo [5 ]
Lin, Ningjing [1 ]
Liu, Weiping [1 ]
Ding, Ning [1 ]
Li, Yexiong [5 ]
Dong, Mei [4 ]
Song, Yuqin [1 ]
Zhu, Jun [1 ]
机构
[1] Peking Univ Canc Hosp & Inst, Dept Lymphoma, Minist Educ Beijing, Key Lab Carcinogenesis & Translat Res, Beijing 100142, Peoples R China
[2] Peking Univ Canc Hosp & Inst, Dept Nucl Med, Natl Med Prod Adm, NMPA Key Lab Res & Evaluat Radiopharmaceut, Beijing 100142, Peoples R China
[3] Peking Univ Canc Hosp & Inst, Dept Radiat Oncol, Beijing 100142, Peoples R China
[4] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Dept Med Oncol, Natl Canc Ctr,Natl Clin Res Ctr Canc,Canc Hosp, Beijing 100021, Peoples R China
[5] Chinese Acad Med Sci & Peking Union Med Coll, Dept Radiat Oncol, Canc Hosp, Natl Canc Ctr,Natl Clin Res Ctr Canc, Beijing 100021, Peoples R China
来源
AGING-US | 2022年 / 14卷 / 21期
基金
中国国家自然科学基金;
关键词
extranodal NK/T-cell lymphoma; induction chemotherapy; response; survival; individualized treatment; BARR-VIRUS DNA; CLINICAL-IMPLICATIONS; PROGNOSTIC-FACTORS; L-ASPARAGINASE; RADIOTHERAPY; RISK; IIE; IE; THERAPY; STRATIFICATION;
D O I
10.18632/aging.204355
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Objective: We aimed to assess the association between induction chemotherapy (CT) response and survivals and to explore an induction CT response-adapted treatment strategy for localized extranodal NK/T-cell lymphoma (NKTCL) receiving first-line sequential CT and radiation (RT). Methods: We retrospectively reviewed the data of patients with localized NKTCL receiving first-line CT+RT from 2010 to 2020 at two independent institutes (primary cohort, n = 203; validation cohort, n = 67). Responses after induction CT (initial response), RT (final response) and survivals were analyzed. Results: Patients with initial complete remission (CR) had higher final CR rate than the others (99.1% vs. 78.7%, P < 0.001). Initial CR was associated with superior 5-year progression-free survival (PFS, 90.0% vs. 61.4% vs. 30.8%, P < 0.001) and overall survival (OS, 93.5% vs. 70.7% vs. 60.6%, P < 0.001), as compared to initial partial remission or non-response. Though majority of cases with initial non-CR achieved final CR after RT, they still had a tendency of shortened OS compared with initial CRs (86.9% vs. 90.6%, P = 0.063). Multivariate analysis demonstrated patients with initial non-CR had higher relapse (HR = 4.748, 95% CI, 2.396-9.407, P < 0.001) and death hazard (HR = 4.296, 95% CI, 1.802-10.24, P = 0.001). Furthermore, more intensive therapy of & GE;6 total cycles of CT yielded significantly superior 5-year OS for patients with initial non-CR (76.7% vs. 54.7%, P = 0.026) rather than patients with initial CR. Conclusion: Deep remission from induction CT was associated with favorable survivals in localized NKTCL receiving CT+RT, and an induction CT response-adapted individualized treatment strategy might be recommended in clinical practice.
引用
收藏
页码:8729 / 8744
页数:16
相关论文
共 50 条
  • [41] Clinical implications of plasma Epstein-Barr virus DNA in early-stage extranodal nasal-type NK/T-cell lymphoma patients receiving primary radiotherapy
    Wang, Zhao-Yang
    Liu, Qing-Feng
    Wang, Hua
    Jin, Jing
    Wang, Wei-Hu
    Wang, Shu-Lian
    Song, Yong-Wen
    Liu, Yue-Ping
    Fang, Hui
    Ren, Hua
    Wu, Run-Ye
    Chen, Bo
    Zhang, Xi-Mei
    Lu, Ning-Ning
    Zhou, Li-Qiang
    Li, Ye-Xiong
    BLOOD, 2012, 120 (10) : 2003 - 2010
  • [42] Concurrent Etoposide, Steroid, High-dose Ara-C and Platinum chemotherapy with radiation therapy in localised extranodal natural killer (NK)/T-cell lymphoma, nasal type
    Michot, Jean-Marie
    Mazeron, Renaud
    Danu, Alina
    Lazarovici, Julien
    Ghez, David
    Antosikova, Anna
    Willekens, Christophe
    Chamseddine, Ali N.
    Minard, Veronique
    Dartigues, Peggy
    Bosq, Jacques
    Carde, Patrice
    Koscielny, Serge
    De Botton, Stephane
    Ferme, Christophe
    Girinsky, Theodore
    Ribrag, Vincent
    EUROPEAN JOURNAL OF CANCER, 2015, 51 (16) : 2386 - 2395
  • [43] Intensity-modulated radiation therapy followed by GDP chemotherapy for newly diagnosed stage I/II extranodal natural killer/T cell lymphoma, nasal type
    Huang, Yu
    Yang, Jianliang
    Liu, Peng
    Zhou, Shengyu
    Gui, Lin
    He, Xiaohui
    Qin, Yan
    Zhang, Changgong
    Yang, Sheng
    Xing, Puyuan
    Sun, Yan
    Shi, Yuankai
    ANNALS OF HEMATOLOGY, 2017, 96 (09) : 1477 - 1483
  • [44] Effectiveness of pegaspargase, gemcitabine, and oxaliplatin (P-GEMOX) chemotherapy combined with radiotherapy in newly diagnosed, stage IE to IIE, nasal-type, extranodal natural killer/T-cell lymphoma
    Wei, Wen
    Wu, Ping
    Li, Li
    Zhang, Zhi-hui
    HEMATOLOGY, 2017, 22 (06) : 320 - 329
  • [45] Risk-dependent curability of radiotherapy for elderly patients with early-stage extranodal nasal-type NK/T-cell lymphoma: A multicenter study from the China Lymphoma Collaborative Group (CLCG)
    Chen, Bo
    Zhu, Su-Yu
    She, Mei
    Su, Hang
    Wang, Ying
    He, Xia
    Xu, Li-Ming
    Yuan, Zhi-Yong
    Zhang, Li-Ling
    Wu, Gang
    Qu, Bao-Lin
    Qian, Li-Ting
    Hou, Xiao-Rong
    Zhang, Fu-Quan
    Zhang, Yu-Jing
    Zhu, Yuan
    Cao, Jian-Zhong
    Lan, Sheng-Min
    Wu, Jun-Xin
    Wu, Tao
    Qi, Shu-Nan
    Yang, Yong
    Liu, Xin
    Li, Ye-Xiong
    CANCER MEDICINE, 2018, 7 (12): : 5952 - 5961
  • [46] Combination of atezolizumab and chidamide to maintain long-term remission in refractory metastatic extranodal natural killer/T-cell lymphoma: A case report
    Wang, Juan
    Gao, Yong-Sheng
    Xu, Kun
    Li, Xiao-Dong
    WORLD JOURNAL OF CLINICAL CASES, 2022, 10 (05) : 1609 - 1616
  • [47] Modern Radiation Therapy for Extranodal Nasal-Type NK/T-cell Lymphoma: Risk-Adapted Therapy, Target Volume, and Dose Guidelines from the International Lymphoma Radiation Oncology Group
    Qi, Shu-Nan
    Li, Ye-Xiong
    Specht, Lena
    Oguchi, Masahiko
    Tsang, Richard
    Ng, Andrea
    Suh, Chang-Ok
    Ricardi, Umberto
    Mac Manus, Michael
    Dabaja, Bouthaina
    Yahalom, Joachim
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 110 (04): : 1064 - 1081
  • [48] Radiation therapy versus chemotherapy as initial treatment for localized nasal natural killer (NK)/T-cell lymphoma: a single institute survey in Taiwan
    You, JY
    Chi, KH
    Yang, MH
    Chen, CC
    Ho, CH
    Chau, WK
    Hsu, HC
    Gau, JP
    Tzeng, CH
    Liu, JH
    Chen, PM
    Chiou, TJ
    ANNALS OF ONCOLOGY, 2004, 15 (04) : 618 - 625
  • [49] Association of improved overall survival with decreased distant metastasis following asparaginase-based chemotherapy and radiotherapy for intermediate- and high-risk early-stage extranodal nasal-type NK/T-cell lymphoma: a CLCG study
    Zheng, X.
    He, X.
    Yang, Y.
    Liu, X.
    Zhang, L. L.
    Qu, B. L.
    Zhong, Q. Z.
    Qian, L. T.
    Hou, X. R.
    Qiao, X. Y.
    Wang, H.
    Zhu, Y.
    Cao, J. Z.
    Wu, J. X.
    Wu, T.
    Zhu, S. Y.
    Shi, M.
    Xu, L. M.
    Zhang, H. L.
    Su, H.
    Song, Y. Q.
    Zhu, J.
    Zhang, Y. J.
    Huang, H. Q.
    Wang, Y.
    Chen, F.
    Yin, L.
    Qi, S. N.
    Li, Y. X.
    ESMO OPEN, 2021, 6 (04)
  • [50] Tislelizumab and radiation therapy in low-risk early-stage extranodal natural killer/T-cell lymphoma, nasal type: a phase II study protocol
    Li, Jia-Ying
    Qi, Shu-Nan
    Hu, Chen
    Liu, Xin
    Yang, Yong
    Wu, Tao
    Zheng, Rong
    Feng, Xiao-Li
    Ni, Xiao-Guang
    Jin, Feng-Yan
    Song, Yu-Qin
    Liu, Wei-Ping
    Zhou, Sheng-Yu
    Li, Ye-Xiong
    FUTURE ONCOLOGY, 2024, 20 (05) : 245 - 256